Stock Price Up 38% This Month
Profitability Improves, Turns to Operating Profit in Q2
Entering the Artificial Skin Organoid Market
The stock price of Rokit Healthcare, a long-term regeneration platform company, has been on an upward trajectory. After its listing in May, the stock underperformed until last month due to concerns about an overhang (potential sell-off volume), but the company's valuation has been steadily increasing this month. Market expectations appear to be rising as the company continues its commercialization efforts based on research and development results.
According to the financial investment industry on September 26, Rokit Healthcare's stock price rose 37.8% to 20,250 won, compared to 14,690 won at the end of last month. During this period, foreign investors and institutional investors recorded cumulative net purchases of 14.8 billion won and 4.1 billion won, respectively.
Rokit Healthcare has developed a patient-specific skin regeneration platform using technologies such as bio-ink production from patients’ own tissues, artificial intelligence (AI) lesion modeling, and 3D bioprinting. Based on its customized organ regeneration platform technology, the company develops and supplies advanced regenerative medical solutions for diabetic foot treatment, skin regeneration, cartilage regeneration, and kidney regeneration.
In the second quarter of this year, the company posted consolidated sales of 6 billion won and an operating profit of 60 million won. Compared to the same period last year, sales increased by 66%, and the company turned to an operating profit.
Kim Hyungyeom, a researcher at KB Securities, stated, "It is important to note that the company turned to profit in the second quarter of this year," adding, "This means that profitability has improved as the overseas market entry and AI-driven hyper-personalized organ regeneration platform business have grown steadily."
Rokit Healthcare is conducting the world’s first global clinical trial for AI-based cartilage regeneration, aiming for fundamental cartilage regeneration beyond simple pain relief.
Not only in Korea but also in the United States and South America, the company is launching randomized clinical trials targeting patients with knee joint cartilage defects. The study will compare the effectiveness and safety of microfracture surgery alone versus a combination of microfracture and the AI cartilage regeneration platform. The company expects that true hyaline cartilage can be regenerated without rejection, making fundamental treatment possible.
Previously, in June, Rokit Healthcare registered its regeneration mechanism and bioprinting know-how with the United States Patent and Trademark Office (USPTO). The company aims to fully enter advanced markets such as the United States, Europe, and Japan starting in the second half of 2027.
Rokit Healthcare is preparing to enter the artificial skin organoid market through the commercialization of its artificial skin organoid, EpiTem-2. EpiTem-2 is a product that precisely replicates both epidermal and full-thickness artificial skin using a 3D printer. It can be applied to various non-clinical tests, including toxicity assessment, sensitization testing, and whitening efficacy evaluation. The product is attracting attention as a solution that can respond to regulatory changes in the United States Food and Drug Administration (FDA) regarding new approach methodologies (NAMs) as alternatives to animal testing.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
